Fundraising Fox

Fogpharma

Boston, US · Founded 2015 · 4 known investors

fogpharma.com ↗

FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases. The company operates a custom-built research platform focused on this peptide modality for drug discovery.

Biotech

Founders & leadership

Fogpharma was founded in 2015 by Gregory L Verdine.

GL
Gregory L VerdineFounder
MM
Mathai MammenCEO, President and Chairman

Investors · 4

Catalio Capital Management, LPNew York
Horizons VenturesHong Kong · $1M – $110M
GV (Google Ventures)reportedMountain View · $250K – $50Mvia Krishna Yeshwant · board
venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$278.4M disclosed across 5 rounds · 2015–2022

▶$178MraisedDec 2022 · 24 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • WeiQing ZhouExecutive Officer
  • Corey S. GoodmanDirector
  • Krishna YeshwantDirector
  • Rick KlausnerDirector
  • Jeffrey A. LeerinkDirector
  • Edward M. FitzgeraldDirector
  • Barbara WeberDirector
  • Gregory L. VerdineExecutive Officer, Director
Offering amount
$178M
Amount sold
$178M
First sale
Nov 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23.3MraisedJan 2021 · 22 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara WeberDirector
  • Krishna YeshwantDirector
  • Leon ChenDirector
  • Edward M. FitzgeraldDirector
  • Jeffrey A. LeerinkDirector
  • Gregory L. VerdineExecutive Officer, Director
  • WeiQing ZhouExecutive Officer
Offering amount
$107M
Amount sold
$23.3M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$65.5MraisedMay 2018 · 24 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Leon ChenDirector
  • WeiQing ZhouExecutive Officer
  • Jeffrey A. LeerinkDirector
  • Edward FitzgeraldDirector
  • Gregory L. VerdineExecutive Officer, Director
Offering amount
$66M
Amount sold
$65.5M
First sale
Feb 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11MraisedAug 2017 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey A LeerinkDirector
  • Edward M FitzgeraldDirector
  • WeiQing ZhouExecutive Officer
  • Gregory L VerdineExecutive Officer, Director
Offering amount
$11M
Amount sold
$11M
Proceeds to insiders
$1.1M
First sale
May 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$625KraisedNov 2015 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory L VerdineExecutive Officer, Director
Amount sold
$625K
Proceeds to insiders
$125K
First sale
Nov 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Fogpharma do?
FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases. The company operates a custom-built research platform focused on this peptide modality for drug discovery.
Who founded Fogpharma?
Fogpharma was founded by Gregory L Verdine in 2015.
Who are Fogpharma's investors?
Fogpharma's investors include Catalio Capital Management, LP, Horizons Ventures, GV (Google Ventures), venBio Global Strategic.
How much funding has Fogpharma raised?
Fogpharma has disclosed $278.4M raised across 5 rounds.
Where is Fogpharma headquartered?
Fogpharma is headquartered in Boston, US.